1,670 Shares in AbbVie Inc. (NYSE:ABBV) Bought by Blue Capital Inc.

Blue Capital Inc. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,670 shares of the company's stock, valued at approximately $297,000.

Several other institutional investors have also modified their holdings of ABBV. Principal Financial Group Inc. lifted its position in shares of AbbVie by 12.3% in the third quarter. Principal Financial Group Inc. now owns 2,487,363 shares of the company's stock valued at $491,204,000 after acquiring an additional 273,078 shares in the last quarter. Nordea Investment Management AB lifted its holdings in AbbVie by 19.3% in the 4th quarter. Nordea Investment Management AB now owns 2,993,734 shares of the company's stock valued at $528,993,000 after purchasing an additional 483,455 shares in the last quarter. Pensionfund Sabic boosted its stake in shares of AbbVie by 36.9% during the 4th quarter. Pensionfund Sabic now owns 19,300 shares of the company's stock worth $3,430,000 after purchasing an additional 5,200 shares during the last quarter. Capital Market Strategies LLC grew its holdings in shares of AbbVie by 0.8% during the fourth quarter. Capital Market Strategies LLC now owns 10,679 shares of the company's stock worth $1,898,000 after buying an additional 89 shares in the last quarter. Finally, Iowa State Bank raised its position in shares of AbbVie by 0.6% in the fourth quarter. Iowa State Bank now owns 53,415 shares of the company's stock valued at $9,492,000 after buying an additional 318 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Stock Up 0.0 %

Shares of AbbVie stock traded up $0.06 during trading hours on Friday, hitting $185.64. 5,303,722 shares of the company's stock traded hands, compared to its average volume of 6,103,278. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $218.66. The company has a market cap of $328.39 billion, a PE ratio of 77.35, a PEG ratio of 1.62 and a beta of 0.56. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The stock has a 50 day simple moving average of $194.70 and a 200-day simple moving average of $187.26.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. AbbVie's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.31 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.53%. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 5,778 shares of AbbVie stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares in the company, valued at approximately $4,429,199.90. This trade represents a 20.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kevin K. Buckbee sold 18,944 shares of the company's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total value of $3,853,399.04. Following the sale, the senior vice president now directly owns 11,496 shares in the company, valued at approximately $2,338,401.36. This represents a 62.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 113,471 shares of company stock valued at $23,426,451. Insiders own 0.08% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ABBV shares. StockNews.com upgraded shares of AbbVie from a "buy" rating to a "strong-buy" rating in a research report on Monday, April 28th. Raymond James reaffirmed an "outperform" rating and issued a $220.00 price objective (up previously from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Wells Fargo & Company increased their target price on AbbVie from $210.00 to $240.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Guggenheim lifted their price target on AbbVie from $214.00 to $216.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Finally, BMO Capital Markets increased their price objective on shares of AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a report on Monday, February 3rd. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $211.41.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.